

Status: Point in time view as at 08/03/2020.

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) No 142/2011, Division Section 3. (See end of Document for details)

ANNEX XIV

IMPORTATION, EXPORT AND TRANSIT

CHAPTER II

SPECIFIC REQUIREMENTS FOR THE IMPORTATION INTO AND TRANSIT THROUGH THE UNION OF ANIMAL BY-PRODUCTS AND DERIVED PRODUCTS FOR USES OUTSIDE THE FEED CHAIN FOR FARMED ANIMALS OTHER THAN FUR ANIMALS

Section 3

Imports of blood and blood products from equidae

The following requirements shall apply to the import of blood and blood products from equidae:

1. [F¹The blood must comply with the conditions set out in point 1(a) of Chapter IV of Annex XIII and must be collected under veterinary supervision:
 - (a) in slaughterhouses:
 - (i) approved in accordance with Regulation (EC) No 853/2004; or
 - (ii) approved and supervised by the competent authority of the country of collection; or
 - (b) from live equidae in facilities approved and furnished with a veterinary approval number and supervised by the competent authority of the country of collection for the purpose of collecting blood from equidae for the production of blood products for purposes other than feeding.]
2. The blood products must comply with the conditions set out in point 2 of Chapter IV of Annex XIII.

In addition, the blood products referred to in point 2(b)(i) of Chapter IV of Annex XIII must be produced from blood collected from equidae which have been kept for a period of at least three months, or since birth if less than three months old, prior to the date of collection on holdings under veterinary supervision in the third country of collection which during that period and the period of blood collection has been free of:

- (a) African horse sickness in accordance with points (a) and (b) of the first subparagraph of Article 5(2) of Directive 2009/156/EC;
- (b) Venezuelan equine encephalomyelitis for a period of at least two years;
- (c) glanders:
 - (i) for a period of three years; or
 - (ii) for a period of six months where the animals have shown no clinical signs of glanders (*Burkholderia mallei*) during the post-mortem inspection in the slaughterhouse referred to in point 1(a), including a careful examination of mucous membranes from the trachea, larynx, nasal cavities and sinuses and their ramifications,

Status: Point in time view as at 08/03/2020.

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) No 142/2011, Division Section 3. (See end of Document for details)

after splitting the head in the median plane and excising the nasal septum;

- (d) [^{F1}in the case of blood products other than serum and plasma, vesicular stomatitis for a period of at least six months.]
3. Blood products must come from an establishment or plant which has been approved or registered by the competent authority of the third country.
4. Blood and blood products shall be packed and labelled in accordance with point 3 of Chapter IV of Annex XIII.

Textual Amendments

- F1** Substituted by Commission Regulation (EU) No 294/2013 of 14 March 2013 amending and correcting Regulation (EU) No 142/2011 implementing Regulation (EC) No 1069/2009 of the European Parliament and of the Council laying down health rules as regards animal by-products and derived products not intended for human consumption and implementing Council Directive 97/78/EC as regards certain samples and items exempt from veterinary checks at the border under that Directive (Text with EEA relevance).

Status:

Point in time view as at 08/03/2020.

Changes to legislation:

There are currently no known outstanding effects for the Commission Regulation (EU) No 142/2011, Division Section 3.